TY - JOUR
T1 - MDR1 C3435T polymorphism and interaction with environmental factors in risk of Parkinson's disease
T2 - A case-control study in Japan
AU - Kiyohara, Chikako
AU - Miyake, Yoshihiro
AU - Koyanagi, Midori
AU - Fujimoto, Takahiro
AU - Shirasawa, Senji
AU - Tanaka, Keiko
AU - Fukushima, Wakaba
AU - Sasaki, Satoshi
AU - Tsuboi, Yoshio
AU - Yamada, Tatsuo
AU - Oeda, Tomoko
AU - Shimada, Hiroyuki
AU - Kawamura, Nobutoshi
AU - Sakae, Nobutaka
AU - Fukuyama, Hidenao
AU - Hirota, Yishio
AU - Nagai, Masaki
N1 - Funding Information:
Received July 4, 2012; Accepted August 6, 2012 J-STAGE Advance Published Date: September 11, 2012, doi:10.2133/dmpk.DMPK-12-RG-075 *To whom correspondence should be addressed: Chikako KIYOHARA, Ph.D., Department of Preventive Medicine, Graduate School of Medical Sciences, Kyushu University, Maidashi 3-1-1, Higashi-ku, Fukuoka 812-8582, Japan. Tel. ©81-92-642-6115, Fax. ©81-92-642-6112, E-mail: chikako@phealth.med.kyushu-u.ac.jp †Other investigators from the Fukuoka Kinki Parkinson’s Disease Study Group are listed in the Appendix. This work was supported in part by Health and Labour Sciences Research Grants, Research on Intractable Diseases, and the Research Committee on Epidemiology of Intractable Diseases from the Ministry of Health, Labour and Welfare, Japan.
PY - 2013
Y1 - 2013
N2 - It has been suggested that P-glycoprotein (P-gp), the product of multidrug resistance 1 (MDR1) gene, regulates the brain entry of various xenobiotics. Impaired function of P-gp may be associated with an increased risk of Parkinson's disease (PD). The aim of this study was to investigate the impact of a MDR1 C3435T polymorphism on PD risk alone or in combination with environmental factors. A total of 238 patients with PD and 368 controls were genotyped for the MDR1 C3435T polymorphism. Subjects with the TT genotype of the C3435T polymorphism showed a nonsignificantly increased risk of PD [odds ratio (OR) = 1.49, 95% confidence interval (CI) = 0.85-2.25] compared with those with the CC genotype. A gene-environment interaction was suggested, with a combination of at least one T allele and ever drinking conferring significantly higher risk (OR = 1.83, 95% CI = 1.07-3.15, p = 0.029), compared with the CC genotype and never drinking. No significant interaction of smoking or occupational pesticide use with the C3435T polymorphism was observed. Our results suggest that the C3435T polymorphism may not play an important role in PD susceptibility in Japanese. Evidence of an interaction between the C3435T polymorphism and alcohol consumption was suggested.
AB - It has been suggested that P-glycoprotein (P-gp), the product of multidrug resistance 1 (MDR1) gene, regulates the brain entry of various xenobiotics. Impaired function of P-gp may be associated with an increased risk of Parkinson's disease (PD). The aim of this study was to investigate the impact of a MDR1 C3435T polymorphism on PD risk alone or in combination with environmental factors. A total of 238 patients with PD and 368 controls were genotyped for the MDR1 C3435T polymorphism. Subjects with the TT genotype of the C3435T polymorphism showed a nonsignificantly increased risk of PD [odds ratio (OR) = 1.49, 95% confidence interval (CI) = 0.85-2.25] compared with those with the CC genotype. A gene-environment interaction was suggested, with a combination of at least one T allele and ever drinking conferring significantly higher risk (OR = 1.83, 95% CI = 1.07-3.15, p = 0.029), compared with the CC genotype and never drinking. No significant interaction of smoking or occupational pesticide use with the C3435T polymorphism was observed. Our results suggest that the C3435T polymorphism may not play an important role in PD susceptibility in Japanese. Evidence of an interaction between the C3435T polymorphism and alcohol consumption was suggested.
UR - http://www.scopus.com/inward/record.url?scp=84876779726&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84876779726&partnerID=8YFLogxK
U2 - 10.2133/dmpk.DMPK-12-RG-075
DO - 10.2133/dmpk.DMPK-12-RG-075
M3 - Article
C2 - 22971641
AN - SCOPUS:84876779726
SN - 1347-4367
VL - 28
SP - 138
EP - 143
JO - Drug metabolism and pharmacokinetics
JF - Drug metabolism and pharmacokinetics
IS - 2
ER -